WHO IS SHALIN SHAH? Founder, CEO, and visionary behind Marius Pharmaceuticals, the company that brought Kyzatrex to market—the first FDA-approved oral testosterone replacement therapy. With a background in private equity and investing, he moved into biotech to solve a long-standing problem in hormone health: making testosterone therapy more accessible, more practical, and aligned with modern lifestyles—while supporting education, stigma reduction, and better men’s health outcomes. In this two-part roundtable, the Biohacking Brothers sit down with Shalin Shah to break down why testosterone is a foundational longevity hormone, how Kyzatrex became the first FDA-approved oral testosterone, and what makes oral pulsatile dosing different from traditional injections. They cover cardiovascular and cognitive implications, stigma and access, fertility concerns, SHBG and free testosterone, estrogen myths, safety markers like hematocrit, and why patient education and proper lab interpretation matter—especially in a world where testosterone levels are declining across younger men.